Rifaximin Versus Lactulose in Renal Failure

Weill Medical College of Cornell University

Overview

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Liver Cirrhosis Renal Failure

Interventions

RifaximinDRUG

400 mg orally

LactuloseDRUG

20 grams titrate to 2-3 bowel movements in one day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * cirrhosis of liver of any etiology * progressive renal failure * stage 0-2 hepatic encephalopathy Exclusion Criteria: * pregnant women

Locations (1)

Weill Cornell Medical Center

New York, New York, United States

Outcomes

Primary Outcomes

slower progression to severe hepatic encephalopathy, stage 3 or 4

Time frame: during hospitalization

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.